Qualcomm Expands Collaboration with Novartis for Connected COPD Therapy
Qualcomm Incorporated (NASDAQ: QCOM) today announced that its subsidiary, Qualcomm Life, Inc., and Novartis are expanding their global connected therapy management collaboration. Novartis will leverage Qualcomm Life's connectivity solutions to power its next-generation connected Breezhaler™, the inhaler for its Chronic Obstructive Pulmonary Disease (COPD) portfolio.
Qualcomm Life is developing the reference design for the small, low-power, disposable module to connect the next generation Breezhaler, which is part of Novartis' leading portfolio of COPD treatments comprised of Onbrez™, Seebri™ and Ultibro™, with Ultibro leading the category in the LABA/ LAMA therapy class. The module is designed to seamlessly connect with Qualcomm Life's 2net™ Platform, and can detect and report inhaler usage, as well as the duration of the patient's inhalation which indicates quality of the inhalation.
"This is an exciting time for health care as we see the proliferation of the Internet of Medical Things," said Rick Valencia, senior vice president and general manager, Qualcomm Life, Inc. "Through our expanded collaboration with Novartis, we are able to deliver a frictionless digital health experience to their COPD patients."
Through this collaboration, Novartis aims to be the first company with a completely integrated, connected delivery device that will provide a simple experience for patients, eliminate the need to assemble the device themselves, and enable them to more easily manage their chronic disease. With near-real time data capture from the patient and the connected device, Novartis aims to improve medication adherence and ultimately health outcomes for COPD patients.
Novartis plans to launch the new connected Breezhaler in 2019 following manufacturing, testing and regulatory approvals.
About Qualcomm Incorporated
Qualcomm Incorporated (NASDAQ: QCOM) is a world leader in 3G, 4G and next-generation wireless technologies. Qualcomm Incorporated includes Qualcomm's licensing business, QTL, and the vast majority of its patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of Qualcomm's engineering, research and development functions, and substantially all of its products and services businesses, including its semiconductor business, QCT. For more than 30 years, Qualcomm ideas and inventions have driven the evolution of digital communications, linking people everywhere more closely to information, entertainment and each other.
2net is a trademark of Qualcomm Incorporated, registered in the United States and other countries.
Most Popular Now
8 - 10 June 2016, Amsterdam, The Netherlands. The Entrepreneurial Village at eHealth Week 2016 will give you the opportunity to meet and connect with the highest profile...Read more
Proposals should develop population-oriented primary prevention interventions to promote mental well-being of young people and assess them for their effectiveness. The ...Read more
IMS MAXIMS has been awarded a place on the Crown Commercial Service (CCS) new Digital Outcomes and Specialists (DOS) Framework. The DOS Framework is one of three compleme...Read more
26 - 27 May, Paris, France. Doctors 2.0 & YOU, the International Digital Health Congress that offers to every health professionals the opportunity to understand how to u...Read more
At the Charing Cross Congress in London, Siemens Healthcare presents the Evar Guidance Engine software application package to support minimally invasive treatment of aort...Read more
When electrical waves in the heart run amok in a condition called arrhythmia, sudden death can occur. To save the life of a patient at risk, doctors currently implant a s...Read more
Most people in the developing world who have asthma, cystic fibrosis or other chronic lung diseases have no way to measure how well their lungs are functioning outside of...Read more
The Grants4Apps (G4A) Accelerator developed by Bayer invites health IT and technology startups to apply for the program's 2016 edition. This year, Bayer looks primarily i...Read more
In experiments involving a simulation of the human esophagus and stomach, researchers at MIT, the University of Sheffield, and the Tokyo Institute of Technology have demo...Read more